1
|
Silva TD, Gonçalves-Santos E, Gonçalves RV, Souza RLM, Caetano JE, Caldas IS, Diniz LF, Marques MJ, Novaes RD. Matrix metalloproteinases inhibition reveals the association between inflammation, collagen accumulation and intestinal translocation of Schistosoma mansoni eggs in vivo. Int Immunopharmacol 2024; 127:111353. [PMID: 38086267 DOI: 10.1016/j.intimp.2023.111353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 12/05/2023] [Accepted: 12/06/2023] [Indexed: 01/18/2024]
Abstract
Schistosomiasis mansoni is a parasitic infection that causes enterohepatic morbidity associated with severe granulomatous inflammation triggered by parasite eggs. In this disease, granulomatous inflammation leads to intestinal erosion and environmental excretion of S. mansoni eggs from feces, an essential process for propagating the parasite and infecting host organisms. Metalloproteinases (MMP) are involved in S. mansoni-induced hepatic granulomatous inflammation and fibrosis. However, the relationship between MMP and collagen accumulation with the intestinal excretion of parasite eggs remains unclear. Thus, the present study investigated whether MMP inhibition is capable of modulating granulomatous inflammation, collagen accumulation and mechanical resistance to the point of influencing the dynamics between intestinal retention and excretion of S. mansoni eggs in infected mice. Our findings indicated that doxycycline (a potent MMP inhibitor) aggravates intestinal inflammation and subverts collagen dynamics in schistosomiasis. By attenuating MMP-2 and MMP-9 activity, this drug is capable of enhancing fibrosis and mechanical resistance of the intestinal wall, hindering S. mansoni eggs translocation. Although collagen content was not correlated with MMP activity, intestinal retention and fecal excretion of parasite eggs in untreated mice; these correlations were observed for doxycycline-treated animals. Thus, our study provides evidence that doxycycline is able to attenuate fecal elimination of S. mansoni eggs by inhibiting MMP-2 and MMP-9 activity, events potentially associated with excessive collagen accumulation, which increases intestinal mechanical resistance and hinders eggs translocation through the intestinal wall. Variations in intestinal collagen dynamics are relevant since they may represent changes in the environmental dispersion of S. mansoni eggs, bringing repercussions for schistosomiasis propagation.
Collapse
Affiliation(s)
- Thiago D Silva
- Programa de Pós-Graduação em Biociências Aplicadas à Saúde, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil
| | - Elda Gonçalves-Santos
- Programa de Pós-Graduação em Biociências Aplicadas à Saúde, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil
| | - Reggiani V Gonçalves
- Departamento de Biologia Animal, Universidade Federal de Viçosa, Viçosa 36570-900, Minas Gerais, Brazil
| | - Raquel L M Souza
- Instituto de Ciências Biomédicas, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil
| | - José Edson Caetano
- Programa de Pós-Graduação em Ciências Biológicas, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil
| | - Ivo S Caldas
- Instituto de Ciências Biomédicas, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil; Programa de Pós-Graduação em Ciências Biológicas, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil
| | - Livia F Diniz
- Instituto de Ciências Biomédicas, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil; Programa de Pós-Graduação em Ciências Biológicas, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil
| | - Marcos J Marques
- Instituto de Ciências Biomédicas, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil; Programa de Pós-Graduação em Ciências Biológicas, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil
| | - Rômulo D Novaes
- Programa de Pós-Graduação em Biociências Aplicadas à Saúde, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil; Departamento de Biologia Animal, Universidade Federal de Viçosa, Viçosa 36570-900, Minas Gerais, Brazil; Instituto de Ciências Biomédicas, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil; Programa de Pós-Graduação em Ciências Biológicas, Universidade Federal de Alfenas, Alfenas 37130-000, Minas Gerais, Brazil.
| |
Collapse
|
2
|
Cavalcante dos Santos R, Cunha FC, Marcellos CFC, de Mello MSL, Tavares FW, Pereira N, Gomes Barreto A. Adsorption of Praziquantel Enantiomers on Chiral Cellulose tris 3-chloro, 4-methylphenylcarbamate by Frontal Analysis: Fisherian and Bayesian Parameter Estimation and Inference. J Chromatogr A 2022; 1676:463200. [DOI: 10.1016/j.chroma.2022.463200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 06/02/2022] [Accepted: 06/04/2022] [Indexed: 11/24/2022]
|
3
|
Zdesenko G, Mutapi F. Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models. PLoS Negl Trop Dis 2020; 14:e0008649. [PMID: 32976496 PMCID: PMC7518612 DOI: 10.1371/journal.pntd.0008649] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Schistosomiasis control is heavily reliant on the drug praziquantel (PZQ), which is used as preventive chemotherapy as part of national helminth control strategies. Given the heavy reliance on PZQ for mass drug administration, there has been considerable research on the potential of parasites developing resistance to the drug, resulting in decreased drug efficacy. However, there have been comparatively fewer studies of other factors that can potentially alter PZQ efficacy. Here, we investigate whether host PZQ metabolism contributes towards variable cure rates. We evaluate factors that can influence the metabolism of PZQ and the resultant effect on the efficacy of PZQ treatment to determine factors that potentially influence an individual's response to the drug. The literature search was directed at published studies from three online databases: Web of Science, PubMed, and EMBASE. The search terms for the review comprised of ([praziquantel OR PZQ] AND [schistosom* OR bilharzia] AND [pharmaco*]) and included studies evaluating PZQ metabolism. Publications were categorised into pharmacokinetics, drug-drug interactions, pharmacogenetics, and metabolite analysis. Forty publications describing human and experimental studies fitted the inclusion criteria and were subjected to data extraction and analysis. The analyses showed that variable exposure to PZQ was associated with alterations in the liver's capacity to metabolise PZQ and observed drug-drug interactions. Other factors influencing the efficacy of PZQ were brand, formulation, and co-administered food. Although some work has been performed on metabolite identification, there was minimal information on PZQ's metabolic pathway, and no pharmacogenetics studies were identified. The study indicated that in both human and experimental studies alterations in the liver's capacity to metabolise PZQ as well as drug-drug interactions affected systemic levels of PZQ that could result in variable cure rates. The study confirmed previous findings of higher antischistosomal activity of (R)-PZQ enantiomer when administered alone compared to the racemate at the same dose as well as improved efficacy when the drug is administered with food. The study also highlighted the need for more comprehensive studies of the PZQ metabolic pathway and PZQ pharmacogenetic studies in humans.
Collapse
Affiliation(s)
- Grace Zdesenko
- Institute of Immunology & Infection Research, University of Edinburgh, Ashworth Laboratories, King’s Buildings, Edinburgh, United Kingdom
- NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA), University of Edinburgh, Ashworth Laboratories, King’s Buildings, Edinburgh, United Kingdom
| | - Francisca Mutapi
- Institute of Immunology & Infection Research, University of Edinburgh, Ashworth Laboratories, King’s Buildings, Edinburgh, United Kingdom
- NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA), University of Edinburgh, Ashworth Laboratories, King’s Buildings, Edinburgh, United Kingdom
| |
Collapse
|
4
|
Matos-Rocha TJ, Cavalcanti MGDS, Barbosa-Filho JM, Lúcio ASSC, Veras DL, Marques MOM, Alves LC, Brayner FA. Ultrastructural study of morphological changes in Schistosoma mansoni after in vitro exposure to the monoterpene rotundifolone. Rev Soc Bras Med Trop 2017; 50:86-91. [DOI: 10.1590/0037-8682-0285-2016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Accepted: 01/17/2017] [Indexed: 01/03/2023] Open
Affiliation(s)
| | | | | | | | - Dyana Leal Veras
- Centro de Pesquisas Aggeu Magalhães, Brazil; Universidade Federal de Pernambuco, Brazil
| | | | - Luiz Carlos Alves
- Centro de Pesquisas Aggeu Magalhães, Brazil; Universidade Federal de Pernambuco, Brazil
| | - Fábio André Brayner
- Centro de Pesquisas Aggeu Magalhães, Brazil; Universidade Federal de Pernambuco, Brazil
| |
Collapse
|
5
|
de Castro AT, Castro AP, Silva MS, de Souza IMM, Martins-Souza RL, Chagas-Paula DA, Coelho LFL, da Silva Bolzani V, Pivatto M, Viegas C, Marques MJ. In vitro evaluation of the schistosomicidal effect of the extracts, fractions and major 3-hydroxy-2,6-dialkyl-substituted piperidine alkaloids from the flowers of Senna spectabilis (Fabaceae). Bioorg Med Chem Lett 2016; 26:4197-204. [DOI: 10.1016/j.bmcl.2016.07.058] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 07/22/2016] [Accepted: 07/23/2016] [Indexed: 01/14/2023]
|
6
|
Katz N, Couto FFB, Araújo N. Imatinib activity on Schistosoma mansoni. Mem Inst Oswaldo Cruz 2015; 108:850-3. [PMID: 24037106 PMCID: PMC3970637 DOI: 10.1590/0074-0276130207] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2013] [Accepted: 06/10/2013] [Indexed: 11/22/2022] Open
Abstract
Imatinib, a drug used for treatment of human chronic myeloid leukaemia, due to
its activity against protein kinases, has been also evaluated in vitro against
Schistosoma mansoni showing high schistosomicidal activity.
In the present experiments imatinib activity in vitro was confirmed at the doses
of 25 µM, 50 µM and 100 µM. The first drug activity observed with the lower dose
was interruption of egg-laying and with the higher dosages was the death of the
worms. In mice infected with S. mansoni no activity was found
even with 1,000 mg/kg/day, 500 mg/kg/day, single oral dose or when administered
for three consecutive days. This is another example of the difference of results
related to in vitro and in vivo trials using S. mansoni
worms.
Collapse
Affiliation(s)
- Naftale Katz
- Fiocruz, Centro de Pesquisas René Rachou, Laboratório de Esquistossomose, Belo HorizonteMG, Brasil
| | | | | |
Collapse
|
7
|
Silva-Moraes V, Couto FFB, Vasconcelos MM, Araújo N, Coelho PMZ, Katz N, Grenfell RFQ. Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms. Mem Inst Oswaldo Cruz 2013; 108:600-4. [PMID: 23903976 PMCID: PMC3970602 DOI: 10.1590/0074-0276108052013011] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2012] [Accepted: 12/18/2012] [Indexed: 12/29/2022] Open
Abstract
Current schistosomiasis control strategies are largely based on chemotherapeutic agents and a limited number of drugs are available today. Praziquantel (PZQ) is the only drug currently used in schistosomiasis control programs. Unfortunately, this drug shows poor efficacy in patients during the earliest infection phases. The effects of PZQ appear to operate on the voltage-operated Ca2+ channels, which are located on the external Schistosoma mansoni membrane. Because some Ca2+ channels have dihydropyridine drug class (a class that includes nifedipine) sensitivity, an in vitro analysis using a calcium channel antagonist (clinically used for cardiovascular hypertension) was performed to determine the antischistosomal effects of nifedipine on schistosomula and adult worm cultures. Nifedipine demonstrated antischistosomal activity against schistosomula and significantly reduced viability at all of the concentrations used alone or in combination with PZQ. In contrast, PZQ did not show significant efficacy when used alone. Adult worms were also affected by nifedipine after a 24 h incubation and exhibited impaired motility, several lesions on the tegument and intense contractility. These data support the idea of Ca2+ channels subunits as drug targets and favour alternative therapeutic schemes when drug resistance has been reported. In this paper, strong arguments encouraging drug research are presented, with a focus on exploring schistosomal Ca2+ channels.
Collapse
Affiliation(s)
- Vanessa Silva-Moraes
- Laboratório de Esquistossomose, Centro de Pesquisas René
Rachou-Fiocruz, Belo Horizonte, MG, Brasil
- Universidade Federal de São João Del Rey, Divinópolis, MG, Brasil
| | | | | | - Neusa Araújo
- Laboratório de Esquistossomose, Centro de Pesquisas René
Rachou-Fiocruz, Belo Horizonte, MG, Brasil
| | - Paulo Marcos Zech Coelho
- Laboratório de Esquistossomose, Centro de Pesquisas René
Rachou-Fiocruz, Belo Horizonte, MG, Brasil
| | - Naftale Katz
- Laboratório de Esquistossomose, Centro de Pesquisas René
Rachou-Fiocruz, Belo Horizonte, MG, Brasil
| | - Rafaella Fortini Queiroz Grenfell
- Laboratório de Esquistossomose, Centro de Pesquisas René
Rachou-Fiocruz, Belo Horizonte, MG, Brasil
- Escola de Farmácia, Universidade de Itaúna, Itaúna, MG, Brasil
| |
Collapse
|
8
|
St John-Smith P, McQueen D, Edwards L, Schifano F. Classical and novel psychoactive substances: rethinking drug misuse from an evolutionary psychiatric perspective. Hum Psychopharmacol 2013; 28:394-401. [PMID: 23881888 DOI: 10.1002/hup.2303] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2012] [Accepted: 02/04/2013] [Indexed: 11/08/2022]
Abstract
In this article, ontogenetic and phylogenetic causes of drug abuse and links to human emotional development are considered. Some evolutionary perspectives (e.g. that under certain conditions, consumption of otherwise toxic alkaloids may confer both physical and cultural advantages) are reviewed. As described in the 'mismatch theory', the capacity of the human genome to evolve defences against toxins has been outstripped by the pace of cultural change and technological development, such as purposeful fermentation of alcohol and more recently distillation of alcohol; purification and chemical manipulation of plant alkaloids; and the engineering of entirely novel psychoactive substances (NPS). The functions of the neurobiological substrates that mediate substance misuse and dependence are reviewed. Reasons are given why NPSs present greater cause for concern than plant-derived substances of abuse. We argue that evolutionary biology provides an important orientation for the research agenda in substance misuse.
Collapse
Affiliation(s)
- Paul St John-Smith
- Hertsmere Community Mental Health Team, Hertfordshire Partnership Foundation Trust, Borehamwood, UK.
| | | | | | | |
Collapse
|
9
|
Kolosionek E, Graham BB, Tuder RM, Butrous G. Pulmonary vascular disease associated with parasitic infection--the role of schistosomiasis. Clin Microbiol Infect 2011; 17:15-24. [PMID: 20636425 DOI: 10.1111/j.1469-0691.2010.03308.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Parasitic diseases have been known to cause pulmonary vascular lesions. Schistosomiasis is the most common parasitic disease associated with pulmonary arterial hypertension, although other trematodes have been implicated. Systematic evaluation of and interest in this problem have been rekindled because of the current availability of pulmonary arterial hypertension treatment.
Collapse
|
10
|
Kolosionek E, Crosby A, Harhay MO, Morrell N, Butrous G. Pulmonary vascular disease associated with schistosomiasis. Expert Rev Anti Infect Ther 2011; 8:1467-73. [PMID: 21133670 DOI: 10.1586/eri.10.124] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In this article we focus on the pathogenesis and clinical characteristics of schistosomiasis infection on the lung vasculature. Overall, the basic biology and understanding of Schistosoma immune responses and their effect on the cardiopulmonary system is limited in both animal and human models, which hinders clinical care and drug development. The inflammatory response to the eggs in the lung appears to contribute to the remodeling of the pulmonary vessels. Portal hypertension caused by parasitemia also appears to contribute to the development of pathophysiologic alterations of the pulmonary vascular bed. Antischistosomal therapy, praziquantel, used for pulmonary hypertension secondary to schistosomiasis usually has no effect, but it is given to prevent further progression of disease. Currently, there are no clinical trials for the treatment of pulmonary vascular disease secondary to schistosomiasis. Specialty drugs such as phosphodiesterase type 5 or tyrosine kinase inhibitors exhibit some interesting activity, yet are prohibitively expensive, lack safety and efficacy studies in schistosomiasis endemic populations, and tend to be limited by safety, efficacy, route of administration and compliance problems.
Collapse
|